Effect of Dexamethasone on Days Alive and Ventilator-Free in Patients With Moderate or Severe Acute Respiratory Distress Syndrome and COVID-19: The CoDEX Randomized Clinical Trial.

M Tomazini, Bruno; S Maia, Israel; B Cavalcanti, Alexandre; Berwanger, Otavio; G Rosa, Regis; C Veiga, Viviane; Avezum, Alvaro; D Lopes, Renato; R Bueno, Flavia; Vitoria A O Silva, Maria; P Baldassare, Franca; L V Costa, Eduardo; A B Moura, Ricardo; O Honorato, Michele; N Costa, Andre; P Damiani, Lucas; Lisboa, Thiago; Kawano-Dourado, Letícia; G Zampieri, Fernando; B Olivato, Guilherme; Righy, Cassia; P Amendola, Cristina; M L Roepke, Roberta; H M Freitas, Daniela; N Forte, Daniel; G R Freitas, Flávio; C F Fernandes, Caio; M G Melro, Livia; F S Junior, Gedealvares; Costa Morais, Douglas; Zung, Stevin; R Machado, Flávia; C P Azevedo, Luciano; COVID-19 Brazil III Investigators, COALITION

doi:10.1001/jama.2020.17021

Public

Effect of Dexamethasone on Days Alive and Ventilator-Free in Patients With Moderate or Severe Acute Respiratory Distress Syndrome and COVID-19: The CoDEX Randomized Clinical Trial.

Shared by NobleBlocks on Oct 6, 2020 • 12:00 AM UTC

Authors:

Bruno M Tomazini

Israel S Maia

Alexandre B Cavalcanti

Abstract

Importance: Acute respiratory distress syndrome (ARDS) due to coronavirus disease 2019 (COVID-19) is associated with substantial mortality and use of health care resources. Dexamethasone use might attenuate lung injury in these patients. Objective: To determine whether intravenous dexamethasone incr...

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!